Charnwood Molecular, a UK-based pre-clinical discovery CRO serving the global pharmaceutical and biotechnology market, has opened its new facilities at Charnwood Campus, Loughborough.
 
Charnwood Molecular has become the sole occupier of a three-story laboratory facility at Charnwood Campus which will house over 150 scientists. With the company’s recent acquisition of Aurelia Bioscience, it is now well prepared for the next phase of its development as a company focused on discovery and innovation. The company is able to provide a fully integrated drug discovery solution to its clients, with teams across all disciplines working in the space.

Increased Capacity

Bringing its new laboratories online has quadrupled the company’s capacity. Not only has this enabled Charnwood Molecular to better serve its existing global client base, many of whom have come on board during a period of strong growth for Charnwood Molecular in recent years, but it will also support further expansion across a range of the company’s services.
 
This includes a host of pre-clinical discovery core activities including assay development, computational and medicinal chemistry, early process research and chemical development as well as a whole suite of others which sit alongside to complement these.
 
The site was officially opened at a formal ceremony on April 7 by Lord-Lieutenant of Leicestershire, Mr. Michael Kapur OBE, who is the Queen’s representative in the county.

New Capabilities

Charnwood Molecular is ideally placed now to offer an ever-expanding number of services.
 
The company’s project-proven capabilities include bioscience, computational chemistry, medicinal chemistry and process research & development. The company can work with clients right through the drug discovery process, from target identification through to lead identification, compound optimization and onwards to scale-up. Time is saved and value added by cutting out inefficiencies along the way, ensuring that clients’ compounds are in the best possible position for future market success.
 
Founder and CEO of Charnwood Molecular, Steve Allin, commented, “The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories provide substantial capacity for future growth and expansion of our current scientific teams, along with the future addition of related drug discovery service lines.”